Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDLR | P01130 | 14/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6783138 | 0.93 | LDLR (0.86) | LDLRALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6781265 | 0.92 | LDLR (0.85) | LDLRALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6781226 | 0.90 | LDLR (0.84) | LDLRALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6780802 | 0.90 | LDLR (1.00) | LDLRALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6781832 | 0.90 | LDLR (1.00) | LDLRALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5897099 | 0.89 | LDLR (0.81) | LDLRALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6787743 | 0.89 | LDLR (1.00) | LDLRALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6777396 | 0.89 | LDLR (0.98) | LDLRALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6778422 | 0.89 | LDLR (1.00) | LDLRALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6786687 | 0.89 | LDLR (0.81) | LDLRALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166730-A1 | Amide derivatives for the treatment of diseases mediated by cytokines | ZENECA LIMITED | 2003-09-04 | — | — | US | claimed |
| JP-2001517620-A | — | — | 2001-10-09 | — | — | JP | claimed |
| EP-1017378-A1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca UK Limited (GB) | 2000-07-12 | — | — | EP | claimed |
| EP-0941084-A1 | RAF KINASE INHIBITORS | ZENECA LIMITED (GB) | 1999-09-15 | — | — | EP | claimed |
| WO-1999015164-A1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ZENECA LIMITED (GB) | 1999-04-01 | — | — | WO | claimed |
| WO-1998022103-A1 | RAF KINASE INHIBITORS | ZENECA LIMITED (GB) | 1998-05-28 | — | — | WO | claimed |
| US-6686467-B2 | INHIBITORS OF THE PRODUCTION OF CYTOKINES SUCH AS TUMOUR NECROSIS FACTOR (HEREINAFTER TNF), FOR EXAMPLE TNF ALPHA , AND VARIOUS MEMBERS OF THE INTERLEUKIN (HEREINAFTER IL) FAMILY, FOR EXAMPLE IL-1, IL-6 AND IL-8 | ZENECA LIMITED (GB) | 2004-02-03 | — | — | US | disclosed |
| US-20030166730-A1 | Amide derivatives for the treatment of diseases mediated by cytokines | ZENECA LIMITED | 2003-09-04 | — | — | US | disclosed |
| US-6498274-B1 | Amide derivatives for the treatment of diseases mediated by cytokines | ZENECA LIMITED (GB) | 2002-12-24 | — | — | US | disclosed |
| EP-1017378-B1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| EP-1017378-A1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca UK Limited (GB) | 2000-07-12 | — | — | EP | disclosed |
| EP-0941084-A1 | RAF KINASE INHIBITORS | ZENECA LIMITED (GB) | 1999-09-15 | — | — | EP | disclosed |
| EP-0941084-A1 | RAF KINASE INHIBITORS | ZENECA LIMITED (GB) | 1999-09-15 | — | — | EP | disclosed |
| WO-1999015164-A1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ZENECA LIMITED (GB) | 1999-04-01 | — | — | WO | disclosed |
| WO-1998022103-A1 | RAF KINASE INHIBITORS | ZENECA LIMITED (GB) | 1998-05-28 | — | — | WO | disclosed |
| WO-1998022103-A1 | RAF KINASE INHIBITORS | ZENECA LIMITED (GB) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166730-A1 | Amide derivatives for the treatment of diseases mediated by cytokines | IL2, IL6, IL6ST | LDLR 2621/4885ALDH1A1 262/4885MEN1 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.